Featured Content

Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center

Osteoporosis Drug Could Benefit Postmenopausal Women with Breast Cancer

(Cancer Research [UK]) July 23, 2015 - The study published in The Lancet, showed that the drugs – called bisphosphonates – reduced the risk of breast cancer coming back, as well as significantly reducing the risk of death, in women diagnosed after their menopause with early-stage breast cancer.

Commentary: Bisphosphonates have been approved for a long time for osteoporosis and for cancer that has metastasized to the...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

'Clash of Titans' About Novel Radiotherapy for Breast Cancer

(Medscape Medical News) July 28, 2015 - A war of words appears to be escalating between two camps of radiation oncologists over the results of a major clinical trial of early-stage breast cancer. It has been called a "clash of titans" by some observers.
read article (free registration required) »

NICE Publishes New Guideline On Most Deadly Form Of Skin Cancer

(NICE) July 28, 2015 - NICE has today (29 July) published its first guideline on melanoma which aims to reduce the numbers of people dying from the disease, and addresses the wide variations across the country in diagnosis and treatment.
read press release »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Osteoporosis Drug Could Benefit Postmenopausal Women with Breast Cancer (Cancer Research [UK])

Bisphosphonates have been approved for a long time for osteoporosis and for cancer that has metastasized to the...posted by: Debu Tripathy, MD

Foundation Medicine Initiates Multi-Center Clinical Study Evaluating Its Circulating Tumor DNA (ctDNA) Assay in Multiple Tumor Types (MarketWatch)

It's clear that serum-based testing of circulating free DNA or possibly circulating tumor cells is the next big...posted by: H. Jack West, MD

Top Oncologists Push Back on ‘Outrageous’ Costs of Cancer Drugs’ (KHN Morning Briefing)

The entire oncology community agrees that pricing of new drugs has become unsustainable. Thank you to all of those...posted by: Dean Gesme, MD

Physician Fee Schedule: A Closer Look (ASCO in Action)

INDEED!!! This really does need a very close look. One of the incentive based modifiers will be for value in...posted by: Thomas Marsland, MD

What Is Value to the Cancer Patient, Oncologist, and Payer? (Medscape Medical News)

So indeed value is what you get....but it is also often in the eye of the beholder.... Clearly it has different...posted by: Thomas Marsland, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Ipsen has 1 new job posted.


Dava Oncology has 1 new job posted.


Bayer has 7 jobs posted.


Seattle Genetics has 3 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
SNSS +13.68%
CBMG +9.45%
NYMX +5.84%
PARD -41.18%
IMMU -17.25%
PGNX -10.51%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: July 2015
Company: Puma Biotechnology
Product: neratinib

Date: August 18, 2015
Company: Seattle Genetics, Inc.
Product: Adcetris® (brentuximab vedotin)

Date: August 27, 2015
Company: Bristol-Myers Squibb Co.
Product: Opdivo® (nivolumab)

See All OBR Radar items»




OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.